¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ "<x&pQZ%  
y AOg\+  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© Oqmg;\pm  
d&u 7]<yDA  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© um[! |g/  
Yx ),6C3  
1.Co-stimulators (or co-stimulating molecules) GRIa8>  
\?&A u  
2.NK-kB YjLe(+ WQ  
B+Z13;}B  
3.Immunoglobulin superfamily hiwIWd:H  
0[)VO[  
4.antigen-presenting cell (APC) j#VIHCz lr  
U^rm: *f  
5.death domain ax_YKJ5#P  
8;#AO8+U7)  
6.CCR and CXCR  rN"Xz  
Obo_Y E  
7.Lectin (or mitogen) aD ESr?  
/.$L"u  
8.Clusters of differentiation, CD) C),7- ?  
nm@']  
9.B7 family {155b0  
?4G(N=/&  
10.Cytotoxic T lymphocyte, CTL) w!`Umll2  
`*yAiv>  
11.IL-15 and IL-15 receptor (IL-15R) ooE{V*Ie  
2\0Oji\6  
12.MHC restriction 1b3(  
mW4%2fD[  
13.Affinity-chromatography f^9&WT  
>uy%-aXiVa  
14.Cyctosprin A, CsA JE!("]&  
)~ z Z'^  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 4o5i ."l  
vM`~)rO@!  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© Zw$ OKU  
G{RTH_p  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ;6m;M63z  
ZL_[4 Y  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ mqFq_UX/ T  
%fhNxR  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ JsQ6l%9  
l,d, T  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© "!L kp2\  
[B9;?G  
ÃâÒßѧרҵ£º GGnp Pp   
Do*n#=  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ .y):Rh^  
n29(!10Px  
Ïû»¯ÄÚ¿Æ£º NL!9U,h5|  
S_Z`so }  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ T~k)uQ  
/1fwl5\  
ѪҺ²¡Ñ§×¨Òµ£º  `w<J25  
g1|w?pI1  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»